NASDAQ
3.72USD
-0.05 (-1.33%)
We have scored 6 news catalysts on Taysha Gene Therapies, Inc. (TSHA) over the past 12 months. The biggest single-day move next to one of them came Jun 25, 2026, when TSHA closed −10.5%: “Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants”. Coverage across the window leans positive (average ticker sentiment +0.18). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.2B
P/E
—
EPS
—
Beta
1.17
52W range
3.455-7.3
Day range
3.64–3.79
Open
3.66
Prev close
3.77
Volume
3.1M
Avg volume
3.3M
Dividend
0.00
IPO
2020-09-24
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Taysha Gene Therapies, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for TSHA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.